인쇄하기
취소

GSK seeks marketing approval for lapatinib ditosylate

Published: 2006-11-17 06:57:00
Updated: 2006-11-17 06:57:00
Last month, GlaxoSmithKline plc (GSK) announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMEA) for approval to market Tykerb (lapatinib ditosylate) in combination with Xeloda (capecitabine), for the treatment of advanced or metastatic ErbB2 (HER2) positive breast cancer in women who have received prior therapy, including Herceptin (trastuzumab). ...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.